Ignite Creation Date:
2024-05-05 @ 11:27 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00040677
Status:
COMPLETED
Last Update Posted:
2011-07-18
First Post:
2002-07-08
Brief Title:
A Study of the Efficacy and Safety of ICA-17043 With or Without Hydroxyurea in Patients With Sickle Cell Anemia
Sponsor:
Icagen
Organization:
Icagen
Study Overview
Official Title:
A Phase II Multicenter Twelve-Week Randomized Double-Blind Placebo-Controlled Parallel-Group Dose-Range-Finding Study of the Efficacy and Safety of ICA-17043 With or Without Hydroxyurea Therapy in Patients With Sickle Cell Anemia
Status:
COMPLETED
Status Verified Date:
2011-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
ICA-17043 is being developed for the chronic treatment of patients with sickle cell disease SCD in both adults and children ICA-17043 is a potent and specific inhibitor of a channel in human red blood cells RBCs that blocks RBC dehydration ICA-17043 is expected to inhibit RBC dehydration and thus should prevent or delay the sickling process By reducing sickled cells an improvement in anemia a reduction in painful crises and ultimately less end-organ disease is anticipated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None